By contrast, HFD‐NLRP3−/− mice (characterized by the absence of both NLRP3 inflammasome activation and mucosal enteric gliotic processes) are less susceptible to the development of mucosal barrier alterations associated with obesity, thus highlighting once again a link among HFD intake, NLRP3 inflammasome activation, enteric gliotic processes and intestinal mucosal barrier alterations. The gene discussed is NLRP3; the disease is obesity due to melanocortin 4 receptor deficiency.